Alira Health

Alira Health

Vaccines

Value Communications

Access comprehensive, tailored communication solutions

Personalized vaccine communication strategy

Access our wide range of value communication solutions, tailored to your vaccine, and designed to deliver commercial success.

Alira Health’s in-house team works closely with you to create a detailed, personalized communication strategy that outlines the differentiating factors of your vaccine.
Our multidisciplinary, industry-leading approach includes:
  • Developing payer value propositions and value dossiers
  • Identifying indication-specific opportunities related to epidemiological situation and burden of disease
  • Highlighting specific value (e.g., MoA, clinical benefit, epidemiology)
  • Defining competitive access positioning in different patient groups, age groups, and market segments
  • Demonstrating robust economic and societal value
  • Developing communication tools to support vaccine uptake

Why choose Alira Health?

As our partner, you’ll benefit from our:

  • Focused attention on your specific needs, individual aspects of your vaccine, and corporate communication strategy
  • In-house industry experts with over 25 years of experience working with the key market stakeholders—from payers to doctors
  • In-depth knowledge and understanding of local and global market dynamics and and communication channels

Working together to transform healthcare

Whether you need to understand which asset best aligns with your long-term strategy, which new market or therapeutic area to explore, or how to expand into another sector, we are ready to help you lead the way.

Contact us
Bernd Schollmeier
Bernd Shollmier
Vice President of Global Market Access Vaccines
We are seeing a lot of traction in the industry, as well as interest in vaccine production. To support companies in a challenging payer environment, we created a dedicated vaccine division in our Global Market Access department to provide a variety of solutions that maximize patient access and the gross-to-net value of the product across the full product lifecycle.

Related News

Events July 18, 2024
UXN Health 2024
Look for patient engagement expert Eduardo Perez onsite in Aarhus to connect on topics like integrating patient voices in solution design.
Co-Design MedTech Patient Engagement Pharma
Articles July 4, 2024
Navigating Market Access for Rare Diseases: The Potential of Real-World Evidence
Our experts answer common questions about the strategic need for real-world evidence to drive market access for rare diseases.
Market Access Rare Disease Real-World Evidence (RWE)
Case Studies June 27, 2024
A Multinational Pharma Targeting Myasthenia Gravis Garners Payer Advice on Market Access
Our client sought to incorporate early payer advice on the MG clinical trial design, identify evidence gaps, and provide insights on the overall development program for the asset.
Market Access Myasthenia Gravis (MG) Rare Disease
Reports May 20, 2024
Innovative Payment Schemes for Medtech in England, Germany, and France
This overview offers high-level details on the innovative payment schemes in England, Germany, and France.
MedTech
Case Studies May 14, 2024
Medtech Company Creates an Early Go-to-Market Strategy for Its Breakthrough IVD Solution
The client needed an early go-to-market strategy for their IVD solution to prepare for product development and launch in key European countries and the US.
IVDR Medical Devices MedTech
Case Studies May 8, 2024
Mid-Size Medtech Company with a Borderline Product Defines Strategy for EU Launch
Medtech company sought support in developing a regulatory strategy for the EU launch of their product with an aggressive timeline to launch.
Medical Devices MedTech Regulatory
Reports May 8, 2024
Value-Based Procurement in Australia
This white paper discusses why value-based healthcare and procurement are solutions in a robust healthcare system and identifies the medical technology sector as a collaborative partner(...)
MedTech Value-Based Contracts
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.